
Please try another search
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through Five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development. The Gene-editing services segment provides the customized gene editing services based on animals as well as cells to meet the needs of basic science research and drug development of the customers; Pre-clinical pharmacology and efficacy evaluation segment provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; Animal models selling segment breeds and sells the animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; Antibody development segment utilises the Group’s own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and Innovative drugs development segment engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Changyuan Yu | 62 | 2020 | Independent Non-Executive Director |
Xiaoyan Liang | 58 | 2020 | Independent Non-Executive Director |
Yiliang Wei | 53 | 2015 | Non-Executive Director |
Haichao Zhang | 45 | 2019 | Senior Operation Director of Animal Center & Executive Director |
Yan Li | 36 | 2015 | Chairman of the Supervisory Committee & Director of the President’s Office |
Kexiang Zhou | 61 | 2018 | Non-Executive Director |
Leidi Zhang | 45 | 2022 | Non-Executive Director |
Yuelei Shen | 55 | 2009 | Chairman of the Board, CEO & GM |
Chunli Sun | 44 | 2020 | Director of Human Resources & Supervisor |
Fengmao Hua | 57 | 2021 | Independent Non-Executive Director |
Jian Ni | 53 | 2009 | Executive Director |
Jiawei Yao | 42 | 2022 | Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review